Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.

Michael Steckel | Miriam Molina-Arcas | Britta Weigelt | Michaela Marani | Patricia H Warne | Hanna Kuznetsov | Gavin Kelly | Becky Saunders | Michael Howell | Julian Downward | David C Hancock
Cell research | 2012

Oncogenic mutations in RAS genes are very common in human cancer, resulting in cells with well-characterized selective advantages, but also less well-understood vulnerabilities. We have carried out a large-scale loss-of-function screen to identify genes that are required by KRAS-transformed colon cancer cells, but not by derivatives lacking this oncogene. Top-scoring genes were then tested in a larger panel of KRAS mutant and wild-type cancer cells. Cancer cells expressing oncogenic KRAS were found to be highly dependent on the transcription factor GATA2 and the DNA replication initiation regulator CDC6. Extending this analysis using a collection of drugs with known targets, we found that cancer cells with mutant KRAS showed selective addiction to proteasome function, as well as synthetic lethality with topoisomerase inhibition. Combination targeting of these functions caused improved killing of KRAS mutant cells relative to wild-type cells. These observations suggest novel targets and new ways of combining existing therapies for optimal effect in RAS mutant cancers, which are traditionally seen as being highly refractory to therapy.

Pubmed ID: 22613949

Associated grants

  • Agency: Cancer Research UK, United Kingdom

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


TopoGEN (tool)

RRID:SCR_003630

An Antibody supplier

View all literature mentions

TreeView (tool)

RRID:SCR_013503

Software to graphically browse results of clustering and other analyses from Cluster.

View all literature mentions

NCI-H460 (tool)

RRID:CVCL_0459

Cell line NCI-H460 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

SK-OV-3 (tool)

RRID:CVCL_0532

Cell line SK-OV-3 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

NCI-H358 (tool)

RRID:CVCL_1559

Cell line NCI-H358 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

HT-29 (tool)

RRID:CVCL_0320

Cell line HT-29 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

A-549 (tool)

RRID:CVCL_0023

Cell line A-549 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

Calu-1 (tool)

RRID:CVCL_0608

Cell line Calu-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

SK-MES-1 (tool)

RRID:CVCL_0630

Cell line SK-MES-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

HCT 116 (tool)

RRID:CVCL_0291

Cell line HCT 116 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

NCI-H520 (tool)

RRID:CVCL_1566

Cell line NCI-H520 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

NCI-H23 (tool)

RRID:CVCL_1547

Cell line NCI-H23 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions